Want to see CVSI full AI Analyst Report?
CVSI Stock Chart & Stats
$0.02
>-$0.01(-5.72%)
At close: 4:00 PM EDT
$0.02
>-$0.01(-5.72%)
Day’s Range― - ―
52-Week Range$0.02 - $0.10
Previous CloseN/A
Volume53.78K
Average Volume (3M)246.65K
Market Cap
$4.49M
Enterprise Value$5.97
Total Cash (Recent Filing)$266.00K
Total Debt (Recent Filing)$1.25M
Price to Earnings (P/E)―
Beta0.50
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding225,829,130
10 Day Avg. Volume158,629
30 Day Avg. Volume246,649
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)7.71
Price to Sales (P/S)0.82
P/FCF Ratio-21.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cost Structure And Cash FlowLower operating expenses, improved adjusted EBITDA and a shift to positive quarterly operating cash flow indicate better cost discipline. Sustaining these gains could move the company toward management’s targeted cash-flow breakeven and reduce dependence on external financing.
Brand Strength And Channel DiversificationLeading natural-retail positioning and a substantial direct-to-consumer channel provide established distribution and customer access. This mix can support consumer data, reduce reliance on individual retailers and help the company launch adjacent wellness products.
Insourcing, Acquisitions And Product ExpansionAcquired capabilities and internal manufacturing can improve supply-chain control, product development speed and gross-margin potential. Diversification into non-cannabinoid products also broadens the addressable wellness market and may reduce dependence on CBD demand.
Bears Say
Declining Revenue And Unit DemandPersistent revenue and unit declines show that category pressure is affecting underlying demand, not merely reported profitability. A shrinking sales base limits operating leverage, weakens negotiating power and makes recovery dependent on successful innovation and share gains.
Negative Cash Generation And Limited LiquidityThe company remains cash-consuming over the trailing year despite recent quarterly improvement, while its cash balance is small relative to operating needs. Continued weakness could force external funding, asset actions or additional financing that limits strategic flexibility.
Regulatory And Competitive Execution RiskRegulatory changes could alter formulations, compliance costs or product availability, while a fragmented and contracting market raises customer-acquisition and retention demands. These structural pressures may delay diversification benefits and keep revenue recovery uncertain.
CV Sciences News
CVSI FAQ
What was CV Sciences Inc’s price range in the past 12 months?
CV Sciences Inc lowest stock price was $0.01 and its highest was $0.10 in the past 12 months.
What is CV Sciences Inc’s market cap?
CV Sciences Inc’s market cap is $4.49M.
When is CV Sciences Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CV Sciences Inc’s earnings last quarter?
Currently, no data Available
Is CV Sciences Inc overvalued?
According to Wall Street analysts CV Sciences Inc’s price is currently Overvalued.
Does CV Sciences Inc pay dividends?
CV Sciences Inc does not currently pay dividends.
What is CV Sciences Inc’s EPS estimate?
CV Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CV Sciences Inc have?
CV Sciences Inc has 225,829,130 shares outstanding.
What happened to CV Sciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CV Sciences Inc?
Currently, no hedge funds are holding shares in CVSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CV Sciences Inc
CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division focuses on the creation, manufacturing, and commercialization of plant-derived dietary supplements and cannabidiol (CBD) products sourced from hemp. These offerings are marketed under various brand identities including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. They serve a wide array of health and wellness sectors such as nutraceuticals, personal care, specialty food items, and pet products. The company distributes these goods through its own digital platforms, other online retailers, a network of chosen distributors, and traditional brick-and-mortar stores. In contrast, the Specialty Pharmaceutical division is dedicated to the research, advancement, and eventual market launch of cannabinoids for the treatment of specific medical conditions. A key project in this segment involves the drug candidate CVSI-007, an innovative combination of CBD and nicotine designed to combat smokeless tobacco use and dependence. Established in 2010, the company was initially known as CannaVest Corp. before officially adopting the name CV Sciences, Inc. in January 2016. Its main corporate offices are located in San Diego, California.
CVSI Earnings Call
Q2 2026
0:00 / 0:00
Technical Analysis
cbdMD
―
Cosmos Holdings
―
IM Cannabis Corp
―
―
Incannex Healthcare Limited Sponsored ADR
―










